Nvidia and Eli Lilly unveiled a co-innovation AI Lab for drug discovery efforts. Nvidia announced a strategic collaboration ...
The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX).
Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
If you are wondering whether Travere Therapeutics at around US$29.11 is priced for opportunity or risk, the next sections ...
Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for ...
The latest health news highlights Vietnam's cigarette tax initiative, the FDA's review extension for Travere's kidney drug, ...
An extension was required to provide time to review additional data requested by the FDA to clarify sparsentan’s clinical benefit.
Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
3d
Dow Jones, S&P 500, Nasdaq open mixed as US inflation data align market expectations — Details here
US stock market today: The benchmark indices on Wall Street — Dow Jones, S&P 500, and Nasdaq opened on a mixed note as ...
A fresh setback on the regulatory front was the development that put a damper on Travere Therapeutics ( TVTX 14.63%) stock on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results